Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Transcription of functionally related constitutive genes is not coordinated.

Gandhi SJ, Zenklusen D, Lionnet T, Singer RH.

Nat Struct Mol Biol. 2011 Jan;18(1):27-34. doi: 10.1038/nsmb.1934. Epub 2010 Dec 5.

2.

IκB kinase overcomes PI3K/Akt and ERK/MAPK to control FOXO3a activity in acute myeloid leukemia.

Chapuis N, Park S, Leotoing L, Tamburini J, Verdier F, Bardet V, Green AS, Willems L, Agou F, Ifrah N, Dreyfus F, Bismuth G, Baud V, Lacombe C, Mayeux P, Bouscary D.

Blood. 2010 Nov 18;116(20):4240-50. doi: 10.1182/blood-2009-12-260711. Epub 2010 Jul 29.

3.

A new DAF-16 isoform regulates longevity.

Kwon ES, Narasimhan SD, Yen K, Tissenbaum HA.

Nature. 2010 Jul 22;466(7305):498-502. doi: 10.1038/nature09184. Epub 2010 Jul 7.

4.

Cytosolic FoxO1 is essential for the induction of autophagy and tumour suppressor activity.

Zhao Y, Yang J, Liao W, Liu X, Zhang H, Wang S, Wang D, Feng J, Yu L, Zhu WG.

Nat Cell Biol. 2010 Jul;12(7):665-75. doi: 10.1038/ncb2069. Epub 2010 Jun 13.

PMID:
20543840
5.

A global network of transcription factors, involving E2A, EBF1 and Foxo1, that orchestrates B cell fate.

Lin YC, Jhunjhunwala S, Benner C, Heinz S, Welinder E, Mansson R, Sigvardsson M, Hagman J, Espinoza CA, Dutkowski J, Ideker T, Glass CK, Murre C.

Nat Immunol. 2010 Jul;11(7):635-43. doi: 10.1038/ni.1891. Epub 2010 Jun 13.

6.

Cellular heterogeneity: do differences make a difference?

Altschuler SJ, Wu LF.

Cell. 2010 May 14;141(4):559-63. doi: 10.1016/j.cell.2010.04.033.

7.

Patterns of basal signaling heterogeneity can distinguish cellular populations with different drug sensitivities.

Singh DK, Ku CJ, Wichaidit C, Steininger RJ 3rd, Wu LF, Altschuler SJ.

Mol Syst Biol. 2010 May 11;6:369. doi: 10.1038/msb.2010.22.

8.

A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations.

Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, McDermott U, Azizian N, Zou L, Fischbach MA, Wong KK, Brandstetter K, Wittner B, Ramaswamy S, Classon M, Settleman J.

Cell. 2010 Apr 2;141(1):69-80. doi: 10.1016/j.cell.2010.02.027.

9.

Involvement of oxidative stress in the relapse of acute myeloid leukemia.

Zhou FL, Zhang WG, Wei YC, Meng S, Bai GG, Wang BY, Yang HY, Tian W, Meng X, Zhang H, Chen SP.

J Biol Chem. 2010 May 14;285(20):15010-5. doi: 10.1074/jbc.M110.103713. Epub 2010 Mar 16.

10.

Identifying single-cell molecular programs by stochastic profiling.

Janes KA, Wang CC, Holmberg KJ, Cabral K, Brugge JS.

Nat Methods. 2010 Apr;7(4):311-7. doi: 10.1038/nmeth.1442. Epub 2010 Mar 14.

11.

Delineating genetic alterations for tumor progression in the MCF10A series of breast cancer cell lines.

Kadota M, Yang HH, Gomez B, Sato M, Clifford RJ, Meerzaman D, Dunn BK, Wakefield LM, Lee MP.

PLoS One. 2010 Feb 15;5(2):e9201. doi: 10.1371/journal.pone.0009201.

12.

Variability in gene expression underlies incomplete penetrance.

Raj A, Rifkin SA, Andersen E, van Oudenaarden A.

Nature. 2010 Feb 18;463(7283):913-8. doi: 10.1038/nature08781.

13.

Heterogeneity in the physiological states and pharmacological responses of differentiating 3T3-L1 preadipocytes.

Loo LH, Lin HJ, Singh DK, Lyons KM, Altschuler SJ, Wu LF.

J Cell Biol. 2009 Nov 2;187(3):375-84. doi: 10.1083/jcb.200904140. Epub 2009 Oct 26.

14.

Non-genetic cell-to-cell variability and the consequences for pharmacology.

Niepel M, Spencer SL, Sorger PK.

Curr Opin Chem Biol. 2009 Dec;13(5-6):556-61. doi: 10.1016/j.cbpa.2009.09.015. Epub 2009 Oct 14. Review.

15.

Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment.

Schafer ZT, Grassian AR, Song L, Jiang Z, Gerhart-Hines Z, Irie HY, Gao S, Puigserver P, Brugge JS.

Nature. 2009 Sep 3;461(7260):109-13. doi: 10.1038/nature08268. Epub 2009 Aug 19.

16.

Synaptic NMDAR activity suppresses FOXO1 expression via a cis-acting FOXO binding site: FOXO1 is a FOXO target gene.

Al-Mubarak B, Soriano FX, Hardingham GE.

Channels (Austin). 2009 Jul-Aug;3(4):233-8. Epub 2009 Jul 24.

17.

Ectopic runx2 expression in mammary epithelial cells disrupts formation of normal acini structure: implications for breast cancer progression.

Pratap J, Imbalzano KM, Underwood JM, Cohet N, Gokul K, Akech J, van Wijnen AJ, Stein JL, Imbalzano AN, Nickerson JA, Lian JB, Stein GS.

Cancer Res. 2009 Sep 1;69(17):6807-14. doi: 10.1158/0008-5472.CAN-09-1471. Epub 2009 Aug 18.

18.

Runx1 is a co-activator with FOXO3 to mediate transforming growth factor beta (TGFbeta)-induced Bim transcription in hepatic cells.

Wildey GM, Howe PH.

J Biol Chem. 2009 Jul 24;284(30):20227-39. doi: 10.1074/jbc.M109.027201. Epub 2009 Jun 3.

19.

Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis.

Spencer SL, Gaudet S, Albeck JG, Burke JM, Sorger PK.

Nature. 2009 May 21;459(7245):428-32. doi: 10.1038/nature08012. Epub 2009 Apr 12.

20.

Non-genetic heterogeneity--a mutation-independent driving force for the somatic evolution of tumours.

Brock A, Chang H, Huang S.

Nat Rev Genet. 2009 May;10(5):336-42. doi: 10.1038/nrg2556. Review.

PMID:
19337290

Supplemental Content

Support Center